Navigation Links
BHR Pharma's SyNAPSe® Trial Reaches Important Enrollment Milestone on Brain Injury Awareness Day
Date:3/21/2012

HERNDON, Va., March 21, 2012 /PRNewswire/ -- As communities in the United States gather in support of Traumatic Brain Injury (TBI) Awareness Day, BHR Pharma, LLC's SyNAPSe® clinical trial reaches an important enrollment milestone.

"Every year, millions of us come together in March to raise awareness for the need for better prevention, rehabilitation and treatments for TBI. Unfortunately, even with more than 75 clinical trials in the past 20 years, no drug treatment has been proven effective for the treatment of TBI," said Thomas W. MacAllister, JD, PhD, President & CEO of BHR Pharma who is joining the brain injury community on Capitol Hill today. "We are excited that on this awareness day we met our 400th patient milestone, bringing us one step closer to potentially having the first ever approved drug treatment for severe TBI. This is truly a critical month for the brain injury community and our clinical trial, not just in the United States, but worldwide."

The trial has enrolled the 400 patients needed for the interim analysis. The primary endpoint for the SyNAPSe trial is the Glasgow Outcome Scale (GOS) at six months post-injury. If the independent Data Safety Monitoring Board responsible for reviewing the study observes overwhelming efficacy from the results of the interim analysis on the first 400 patients, the board may recommend that BHR make an early submission to the FDA, potentially shortening the timeline for approval of the acute intravenous treatment BHR-100.

This year's Brain Injury Awareness Month theme is "Anytime, Anywhere, Anyone – Brain Injuries Do Not Discriminate." Each year, an estimated 1.7 million people sustain a TBI and it is a contributing factor to a third of all injury-related deaths in the United States. BHR Pharma supports the Brain Injury Awareness Month campaign and recognizes that brain injuries are a global problem and can affect anyone.

"While recent reports have focused o
'/>"/>

SOURCE BHR Pharma, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
2. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
3. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
4. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
5. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
6. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
7. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
8. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
9. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
11. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... VIEW, Calif. , July 24, 2014  IRIDEX ... it will release its second quarter 2014 financial results ... 2014. In conjunction with the release, the Company ... at 5:00 p.m. Eastern Time on ... of the quarter and other business developments. ...
(Date:7/24/2014)... 2014 Omnicell, Inc. (NASDAQ: ... supply management solutions and analytics software for healthcare ... to discuss the Company,s Second Quarter 2014 financial ... earnings conference call and webcastWhen: , July ... chairman, president and chief executive officer ...
(Date:7/24/2014)... N.J., July 24, 2014  IGI Laboratories, Inc. (NYSE MKT: ... manufacturing company, announced its financial results for the second quarter ... , Total revenues of $6.5 million in the ... same quarter in 2013 , Total revenues of $13.3 ... increase of 78% over the same period in 2013 ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... New results from the largest multicenter clinical trial for ... the International Society for Heart & Lung Transplantation (ISHLT) ...  Results show clinical benefit for the use of Everolimus ... 721 randomized patients at 67 medical centers spanning 5 ...
... April 14, 2011 Oxford Finance Corporation (Oxford), a ... a $2 million equipment loan with Synta Pharmaceuticals Corp. ... compounds for use in Synta,s ongoing clinical trials in ... "Synta Pharmaceuticals has a diverse drug pipeline, including ...
Cached Medicine Technology:Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 2Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 3Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 4Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp. 2
(Date:7/25/2014)... when genes are switched on or off plays a ... regulate metabolism, UT Southwestern Medical Center researchers have found., ... treat obesity and diabetes, since the transcription factor involved ... to influence the body,s sensitivity to insulin and leptin ... body,s regulation of food intake and sugar disposal, and ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Innerspire, LLC ... joined the company as a Creative Enrollment Specialist. In ... relationship building skills as well as his accomplished design ... small business clients, and to service the creative ... Additionally, Greg will work with small business owners and ...
(Date:7/25/2014)... The American Brain Tumor Association (ABTA) ... CommYOUnity™” during its annual patient and family conference in ... brain tumor community as we – the first and ... services and funding brain tumor research – extend our ... tumor awareness and getting our materials and services into ...
(Date:7/25/2014)... July 25, 2014 There are 700,000 people ... diagnosed each day. Though when someone hears the words, “you ... are unsure of the next step and where to turn. ... figure out that next step by providing and pursuing the ... than Brian Olson, member of the ABTA’s Board of Directors ...
(Date:7/25/2014)... Progress in understanding the molecular genetics of brain ... brain tumor treatments, according to Patrick Wen, MD, professor ... for Neuro-Oncology, Dana-Farber Cancer Institute. , At the American ... in Chicago, July 25-26, Dr. Wen will moderate a ... the development of new treatments and advancing strategies to ...
Breaking Medicine News(10 mins):Health News:Manipulating key protein in the brain holds potential against obesity and diabetes 2Health News:Innerspire, LLC Continues National Expansion 2Health News:Innerspire, LLC Continues National Expansion 3Health News:Innerspire, LLC Continues National Expansion 4Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 3Health News:American Brain Tumor Association Board of Directors Member Shares Story of Brain Tumor Survivorship 2Health News:American Brain Tumor Association Board of Directors Member Shares Story of Brain Tumor Survivorship 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 2Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 4
... its truth when then Researchers of Arizona University did a ... D.Martinez and collegues , girls who become overweight or obese ... have a sevenfold increased risk of developing asthma .The boys ... if they are obese , the researchers say. , The ...
... research that suggests high doses of vitamin E may ... prevalent diseases in the world with many ravaging complications, ... heart disease, eye damage, kidney failure, non healing ulcers ... of the nervous system. ,Diabetes is caused by ...
... of Pfizer. The pharmaceutical giant has announced that it ... by the AIDS virus. The decision by the Pfizer comes ... a landmark case against pharmaceutical companies. In an announcement ... be given free of cost to battle HIV through a ...
... Azad Medical College, New Delhi has created history of ... from the American patent office for his technique in ... ,A few weeks ago the American patent office granted ... was able to regenerate organs like the uterus, urethra ...
... West is now sitting up and taking in the aroma ... spices are now the subjects of research by scientists at ... C. Fung and colleagues who conducted the study opine that ... can also double up as an anti bacterial agent. ...
... a little quality time with one's spouse and other partners ... pressure. In a study that used portable monitors to ... pressure was lowest when they were with their partners, regardless ... of the State University of New York, the lead study ...
Cached Medicine News: